Aspirin Combined With Clopidogrel Versus Intravenous Alteplase for Acute Minor Stroke
Status:
Not yet recruiting
Trial end date:
2027-07-01
Target enrollment:
Participant gender:
Summary
An open-label, blinded endpoint, randomized controlled trial that includes patients diagnosed
with non-disabling, non-large vessel occlusion, acute minor stroke within 4.5 hours of onset.
Eligible participants would be randomly assigned to the thrombolysis group (intravenous
alteplase) and the dual antiplatelet group (oral aspirin plus clopidogrel). The primary
outcome is the proportion of the excellent functional outcome (modified Rankin scale 0-1) at
90 days.
Phase:
Phase 4
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University